DoW Alzheimer’s Transforming Research Award
Dept. of Defense — CDMRP · Other Federal · HT942526AZRPTRRA
Source: Grants.gov · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- $4M total
- DeadlineFinal application due date.
- Sep 24, 2026
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- —
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- 4
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- Unknown
- Open dateWhen applications open (or opened).
- May 1, 2026
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- $4M total
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Unspecified
Research areas
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Research Award (TrRA) supports non-incremental, robust, well-designed research that drives transformative advancements in reducing risk and preventing the development of Alzheimer’s disease and/or Alzheimer's disease related dementias (AD/ADRD). Distinctive Features: • Applications must address at least one of the following focus areas: ○ Risk Factor Knowledge: Research that advances understanding, identification, and/or validation of risk and/or protective factors, with research outcomes/products focused on accelerating solutions. Projects may include, but are not limited to, research on environmental, epigenetic, genetic, lifestyle, occupational, or other risks not listed here. ○ Risk Reduction Solutions: Research that describes methods, technologies, and strategies that contribute to reducing risk and preventing AD/ADRD. • Clinical research is allowed, however clinical trials and animal research are prohibited. • Preliminary data are required. • Community collaboration is required for research prospectively enrolling human subjects. • Career Initiation or Transition (CIT) Partnership Option: The TrRA includes an option for more than one PI and supports both new and existing collaborative partnerships. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). If utilizing this option, at least one independent investigator must meet